These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 9327906

  • 1. Catechol O-methyltransferase: characterization of the protein, its gene, and the preclinical pharmacology of COMT inhibitors.
    Männistö PT.
    Adv Pharmacol; 1998; 42():324-8. PubMed ID: 9327906
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Positron emission tomography in drug evaluation: influence of three different catechol-O-methyltransferase inhibitors on metabolism of [NCA] 6-[18F]fluoro-L-dopa in rhesus monkey.
    Günther I, Psylla M, Reddy GN, Antonini A, Vontobel P, Reist HW, Zollinger A, Nickles RJ, Beer HF, Schubiger PA.
    Nucl Med Biol; 1995 Oct; 22(7):921-7. PubMed ID: 8547890
    [Abstract] [Full Text] [Related]

  • 4. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat.
    Männistö PT, Tuomainen P, Tuominen RK.
    Br J Pharmacol; 1992 Mar; 105(3):569-74. PubMed ID: 1628144
    [Abstract] [Full Text] [Related]

  • 5. COMT inhibition: a new treatment strategy for Parkinson's disease.
    Kurth MC, Adler CH.
    Neurology; 1998 May; 50(5 Suppl 5):S3-14. PubMed ID: 9591516
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of three types of catechol O-methylation inhibitors on L-3,4-dihydroxyphenylalanine-induced circling behaviour in rats.
    Törnwall M, Männistö PT.
    Eur J Pharmacol; 1993 Nov 30; 250(1):77-84. PubMed ID: 8119326
    [Abstract] [Full Text] [Related]

  • 9. COMT inhibition in the treatment of Parkinson's disease.
    Ruottinen HM, Rinne UK.
    J Neurol; 1998 Nov 30; 245(11 Suppl 3):P25-34. PubMed ID: 9808337
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice.
    Marsala SZ, Gioulis M, Ceravolo R, Tinazzi M.
    Clin Neuropharmacol; 2012 Nov 30; 35(4):185-90. PubMed ID: 22805229
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. COMT inhibitors: management of Parkinson's disease.
    Mov Disord; 2002 Nov 30; 17 Suppl 4():S45-51. PubMed ID: 12211139
    [No Abstract] [Full Text] [Related]

  • 14. [Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone].
    Arnold G, Kupsch A.
    Nervenarzt; 2000 Feb 30; 71(2):78-83. PubMed ID: 10703007
    [Abstract] [Full Text] [Related]

  • 15. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.
    Napolitano A, Bellini G, Borroni E, Zürcher G, Bonuccelli U.
    Parkinsonism Relat Disord; 2003 Jan 30; 9(3):145-50. PubMed ID: 12573869
    [Abstract] [Full Text] [Related]

  • 16. Effects of selective catechol-O-methyltransferase inhibitors on single-trial passive avoidance retention in male rats.
    Khromova I, Voronina T, Kraineva VA, Zolotov N, Männistö PT.
    Behav Brain Res; 1997 Jun 30; 86(1):49-57. PubMed ID: 9105581
    [Abstract] [Full Text] [Related]

  • 17. The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
    Gerlach M, Xiao AY, Kuhn W, Lehnfeld R, Waldmeier P, Sontag KH, Riederer P.
    J Neural Transm (Vienna); 2001 Jun 30; 108(2):189-204. PubMed ID: 11314772
    [Abstract] [Full Text] [Related]

  • 18. Modulation of rat brain endogenous dopamine metabolism by new inhibitors of catechol O-methyltransferase.
    Törnwall M, Tuomainen P, Männistö PT.
    Eur J Pharmacol; 1993 Aug 03; 239(1-3):39-45. PubMed ID: 8223912
    [Abstract] [Full Text] [Related]

  • 19. COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).
    Jorga KM, Nicholl DJ.
    Br J Clin Pharmacol; 1999 Sep 03; 48(3):449-52. PubMed ID: 10510160
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.